Clinical Trials · NCT05607680
A Study of IBI362 in Participants With Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 610
- Start date
- Nov 2022
- Locations
- 23 sites, China
- Primary endpoint
- Percent Change from Baseline in Body Weight